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Abstract
The immediately-early response gene 5 (IER5) has been reported to be induced by c-ray irradiation and to play a role in the
induction of cell death caused by radiation. We previously identified IER5 as one of the 2,3,4-tribromo-3-methyl-1-
phenylphospholane 1-oxide (TMPP)-induced transcriptional responses in AML cells, using microarrays that encompassed
the entire human genome. However, the biochemical pathway and mechanisms of IER5 function in regulation of the cell
cycle remain unclear. In this study, we investigated the involvement of IER5 in the cell cycle and in cell proliferation of acute
myeloid leukemia (AML) cells. We found that the over-expression of IER5 in AML cell lines and in AML-derived ALDH
hi (High
Aldehyde Dehydrogenase activity)/CD34
+ cells inhibited their proliferation compared to control cells, through induction of
G2/M cell cycle arrest and a decrease in Cdc25B expression. Moreover, the over-expression of IER5 reduced colony formation
of AML-derived ALDH
hi/CD34
+ cells due to a decrease in Cdc25B expression. In addition, over-expression of Cdc25B restored
TMPP inhibitory effects on colony formation in IER5-suppressed AML-derived ALDH
hi/CD34
+ cells. Furthermore, the IER5
reduced Cdc25B mRNA expression through direct binding to Cdc25B promoter and mediated its transcriptional attenuation
through NF-YB and p300 transcriptinal factors. In summary, we found that transcriptional repression mediated by IER5
regulates Cdc25B expression levels via the release of NF-YB and p300 in AML-derived ALDH
hi/CD34
+ cells, resulting in
inhibition of AML progenitor cell proliferation through modulation of cell cycle. Thus, the induction of IER5 expression
represents an attractive target for AML therapy.
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Introduction
Acute myeloid leukemia (AML) is characterized by the excess
production of leukemic blasts arrested at various stages of granu-
locytic and monocytic differentiation. To effectively cure a patient
with AML, this proliferation of leukemic cells must be halted.
Given that chemotherapy rarely eradicates the leukemic clones,
efforts are now being made to find innovative new therapies which
inhibit the proliferation of AML cells. However, the effect of cell
cycle progression and apoptosis resistance on the pathogenesis of
AML remains to be defined. Against these backgrounds, we have
synthesized new bioactive agents and then investigated these anti-
leukemic effects. We previously reported that the phospha sugar
derivative, 2,3,4-tribromo-3-methyl-1-phenylphospholane 1-oxide
(TMPP), was synthesized in the reaction of 3-methyl-1-phenyl-2-
phospholene 1-oxide with bromine, and we investigated the
potential of TMPP as an anti-leukemic agent using AML-derived
ALDH
hi cells [1]. This agent induced a G2/M cell cycle block
through a reduction in cell cycle progression signals (FOXM1,
KIS, Cdc25B, Cyclin D1, Cyclin A, and Aurora-B), resulting in
inhibition of leukemia cell proliferation [1]. We also observed that
down-regulation of FOXM1 inhibited proliferation, and demon-
strated that TMPP suppressed FOXM1 expression, and that this
FOXM1 repression reduced Cyclin B1 and Cdc25B mRNA
expression, resulting in inhibition of the proliferation of AML-
derived ALDH
hi cells [2]. Thus, we demonstrated that TMPP-
mediated FOXM1 repression induced G2/M cell cycle arrest
through a reduction in Cyclin B1 and Cdc25B expression. How-
ever, TMPP and FOXM1 regulate many mitotic regulators in
AML cells. It is unclear how TMPP predominantly induces G2/M
cell cycle arrest rather than G1 cell cycle arrest in AML cells.
To identify TMPP-induced transcriptional responses in AML
cells, TMPP-induced transcriptional alterations were investigated
using microarrays that encompassed the entire human genome.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28011About 180 genes, which belong to functional categories such as the
DNA damage response, regulation of cell cycle and cell proli-
feration, and signaling pathways, responded to TMPP treatment
at the transcriptional level in AML cells. Of these genes, the
immediate-early response gene 5 (IER5) was identified as a key
regulator of the G2/M cell cycle transition.
The immediate-early genes (IER), which are rapidly induced by
growth factors or other various stimuli, encompass a variety of
different protein families (Fos and Jun family of transcriptional
regulators; Myc; zinc-finger proteins; secreted cytokines; cytoplas-
mic proteins, and integral membrane proteins) [3]. Activation of
IER is an important initial step in the regulation of cellular and
genomic responses to external stimuli. Approximately 100 IER
genes have been described to date, and are subdivided into two
classes (fast-kinetics and slow-kinetics) based on their activation
kinetics [4]. The fast-kinetics IER genes (e.g., c-Fos) contain serum
response elements (SRE), which are required for transcriptional
induction. In contrast, the slow-kinetics IER genes, which lack
SRE, display a relatively slower induction and longer persistence
profile following stimulation compared with the fast-kinetics IER
genes [5]. The IER5 gene, which has been identified as a member
of the IER gene family, belongs to the slow-kinetics IER genes, and
is rapidly induced by stimulation with serum or with the growth
factors FGF or PDGF [6]. It has been also reported that IER5
mRNA is induced in the cerebral cortex of rats during waking and
sleep deprivation [7], or in the brains of mouse embryos exposed
to teratogenic valpronic acid (VPA) [8]. The IRE5 mRNA was
induced within 30 min after serum-exposure and at least 180 min
after the serum-stimulation, but its expression was not inhibited by
cycloheximide [6]. IER5 is also upregulated by ionizing radiation
at doses ranging from 0.02 to 10 Gy in lymphoblastoid AHH-1
cells [9,10]. Moreover, it has been reported that suppression of
IER5 increased HeLa cell proliferation, mitigated the inhibition of
proliferation imposed by irradiation, and potentiated radiation-
induced arrest at the G2/M transition [11]. These results
demonstrated that IER5 expression plays an important role in
radiation-mediated cell death and cell cycle checkpoints.
It has been reported that inhibition of cell proliferation in AML
cells is associated with a decrease in the expression of the Cdc25B
phosphatase [12], and that this phosphatase participates in G2/M
checkpoint recovery and its expression is upregulated in acute
myeloid leukemia cells [13]. Therefore, depletion of Cdc25B
might be expected to strongly induce G2/M cell cycle arrest in
AML cells. As previously reported, siRNA-mediated depletion of
FOXM1 expression, or TMPP treatment, induced G2/M cell
cycle arrest and inhibited AML cell proliferation through a
decrease in protein expression of mitotic regulators such as
Cdc25B in AML cells [1,2]. However, it is unclear how Cdc25B
expression is regulated.
In this study, we investigated the function of IER5 in leukemia
cell proliferation. We found that IER5 expression inhibited the
proliferation of both leukemia cell lines and of leukemic blast cells
derived from AML through the transcriptional repression of
Cdc25B.
Results
The expression of IER5 mRNA in acute myeloid leukemia
cells
We first determined the relative expression of IER5 mRNA in
the leukemia cell lines KG-1, Kasumi-1, U937 and YRK2. As
shown in Fig. 1, IER5 mRNA was constitutively expressed in these
AML cell lines. Interestingly, we found that the mRNA expression
of IER5 increased in these AML cell lines compared to untreated
cells, when treated with TMPP (5 and 10 mM) for 24 h. However,
Ara-C (1 mM) did not affect IER5 mRNA expression in these
AML cell lines. Furthermore, we quantified the level of IER5
mRNA in the AML cell lines using quantitative RT-PCR. This
analysis indicated that the expression of IER5 mRNA in the
TMPP-treated leukemia cells was increased 1.78 to 2.29-fold
relative to its expression in untreated cells.
We next determined the relative expression levels of IER5
mRNA and protein in U937 cells. As shown in Fig. 1B, both IER5
mRNA and protein in U937 cells were overexpressed following
transfection with IER5 cDNA or treatment with TMPP compared
to untransfected and untreated U937 cells, respectively. In
contrast, transfection with IER5 shRNA-#1o r- #2 decreased
the expression of both IER5 mRNA and protein in U937 cells
compared to untransfected U937 cells. Moreover, the mRNA and
protein expression of IER5 in other AML cell lines (KG-1,
Kasumi-1 and YRK2) was similarly increased by IER5 cDNA
transfection and suppressed by IER5 shRNA transfection (data not
shown). Thus, IER5 mRNA and protein were constitutively
expressed in all four AML cell lines, although their expression in
AML cell lines were at lower levels compared to normal ALDH
hi/
CD34
+ cells (data not shown). Treatment with TMPP increased
both the mRNA and the protein level of IER5 in AML cells.
Effects of IER5 expression on AML cell proliferation
Since IER5 expression was induced by TMPP in AML cells, we
next examined the functional importance of IER5 expression. For
this purpose, we transfected U937 cells with IER5 cDNA, and
assessed the effect of IER5 over-expression on AML cell
proliferation over 72 h of culture, starting from day 3 post-
transfection. Cell proliferation was measured by cell counting
using a hemocytometer (Fig. 2A, upper panel). When U937 cells
were transfected with IER5 cDNA, cell proliferation was inhibited
compared to non-transfected control cells. Treatment with TMPP
(5 mM) also significantly inhibited the proliferation of U937 cells.
However, the viability of AML cells transfected with IER5 cDNA
or treated with TMPP was almost same as that of the untreated
cells (Fig. 2A, bottom panel). In addition, the expression of IER5
mRNA was significantly increased by TMPP treatment compared
to untreated cells (Fig. 2B, upper panel). We further examined the
effect of IER5 induction on AML cell proliferation by flow
cytometric analysis of the effect of IER5 on cell cycle distribution.
As shown in Fig. 2C and 2D, analysis of U937 cells on day 3 post
cDNA-transfection or post-TMPP treatment indicated an increase
in the percentage of cells in S and G2/M, but not in sub-G1,
compared to control DNA-transfected and untreated cells. No
increase in the polyploid (.4N) population of these cells was
observed. On the other hand, when U937 cells were transfected
with IER5 shRNA-#1o r- #2, each cell cycle distribution was not
affected compared to scrambled shRNA-transfected cells. In
contrast, the population of G2/M was significantly reduced
following TMPP treatment. Moreover, we determined the effect of
IER5 over-expression and TMPP treatment on markers of
apoptosis. We analyzed the effects on loss of mitochondrial
membrane potential, which was determined by flow cytometric
analysis of DiOC6 uptake. Loss of mitochondrial membrane
potential is known to occur in apoptotic cells and precedes the
activation of caspases. DiOC6 fluorescence of U937 cells was not
reduced 3 days after transfection with IER5 cDNA or TMPP
treatment, and DiOC6 fluorescence of IER5 cDNA-transfected or
TMPP treated cells compared to control cells was observed in the
almost same levels (Fig. 2E). The IER5 over-expression and
TMPP treatment similarly induced G2/M cell cycle arrest, but not
apoptosis in other AML cell lines (KG-1, Kasumi-1 and YRK2)
IER5 Induced G2/M Cell Arrest
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e28011Figure 1. IER5 mRNA and protein expression in AML cells. A. RT-PCR was performed to analyze IER5 mRNA expression in AML cell lines (KG-1,
Kasumi-1, U937, and YRK2) treated with or without TMPP (5 and 10 mM) or Ara-C (1 mM) for 24 h. GAPDH mRNA expression is shown as an internal
control. RT-PCR results representative of three independent experiments are shown. Relative levels of IER5 mRNA expression in AMLs were measured
using QRT-PCR. B. IER5 mRNA and protein expression in U937 cells that were transfected with IER5 cDNA, shRNA-#1, or -#2, or were treated with
TMPP (5 mM), were assessed using RT-PCR and QRT-PCR, and Western blotting, respectively. Actin was immunoblotted as a loading control. The
expression levels of the target mRNAs were normalized to the expression of GAPDH mRNA. The results are expressed relative to the untreated control
which was set at 1. Each RT-PCR assay was performed at least three times, and the results are expressed as means 6 SD. *P,0.01. Western blotting
results representative of three independent experiments are shown.
doi:10.1371/journal.pone.0028011.g001
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induced a block in the G2/M phase in AML cells, but did not
induce apoptosis, and therefore demonstrated that induction of
IER5 expression strongly inhibited AML cell proliferation.
Effects of IER5 knock-down on AML cell proliferation
To further examine the functional importance of IER5
expression in AML cells, we next examined the effect of IER5
knock-down on AML cell proliferation. U937 cells were trans-
fected with IER5 shRNA-#1o r- #2, and the effect of IER5
knock-down on AML cell proliferation was assessed over 72 h of
culture, starting from day 3 day post-transfection (Fig. 3). Cell
proliferation was measured by counting the cells using a
hemocytometer (upper panels). When U937 cells were transfected
with IER5 shRNA-#1o r- #2 (Fig. 3A and 3B, respectively), cell
proliferation was slightly increased compared to both untreated
Figure 3. Effect of IER5 knock-down on AML cell proliferation. U937 cells were transfected with IER5 shRNA-#1 (A) or -#2 (B). After 3 days, the
cells were treated with TMPP (5 mM) for 24, 48 and 72 h and the number of viable cells was counted (upper panels). The IER5 mRNA level was
analyzed using quantitative RT-PCR and the level was determined relative to that of GAPDH (bottom panels). The results are means 6 SD from three
independent experiments.
doi:10.1371/journal.pone.0028011.g003
Figure 2. Over-expression of IER5 inhibited AML cell proliferation. A. The cell proliferation of U937 cells, transfected with IER5 cDNA or
treated with TMPP, was measured by counting cells using a hemocytometer (upper panel). Cell counting was started 3 days after transfection, and
was performed every 24 h for 3 days. Data are shown as means 6 S.D. of triplicate cultures and are representative of three independent experiments.
*P,0.01 compared with untransfected control cells. Cell viability of the IER5 over-expressing U937 cells was assessed by counting of viable cells using
trypan blue staining at 72 h, starting 3 days after DNA transfection (bottom panel). B. QRT-PCR analysis of IER5 mRNA expression in untreated cells,
IER5 cDNA-transfected cells, and TMPP-treated U937 cells. QRT-PCR was started 3 days after transfection, and was performed every 24 h for 3 days.
Data are shown as means 6 S.D. of triplicate cultures and are representative of three independent experiments. The levels of the quantified RT-PCR
products were normalized to GAPDH expression in the same sample and were then expressed relative to the mRNA level of a normal control, which
was assigned a value of 1. *P,0.01 compared with untransfected control cells. The protein expression of IER5 in cells was analyzed after 3 days of
culture (bottom panels). Blotting of Actin was used as a loading control. C. The cell cycle distribution of U937 cells that were transfected with control
DNA, IER5 cDNA, scrambled shRNA, IER5 shRNA #1, IER5 shRNA #1, or were treated with TMPP, was analyzed using flow cytometric analysis. The
transfected or TMPP-treated U937 cells were harvested after 3 days. The fraction of cells in the G1, S and G2/M stage of the cell cycle was determined.
Data are shown as means 6 S.D. of triplicate cultures. The IER5 mRNA expression of the cells is shown at bottom and was assessed using RT-PCR. The
RT-PCR results are representative of three independent experiments. Data are shown as means 6 S.D. of triplicate cultures. *P,0.01 compared with
control cells. D and E. Cell cycle analysis (D) and changes of mitochondrial membrane potential (DYm) (E) in IER5 overexpressed or TMPP treated AML
cells. U937 cells were transfected with IER5 cDNA or treated with TMPP (5 mM). Mitochondrial membrane potential was determined 3 days after
transfection or TMPP treatment by staining of the cells with DiOC6 followed by flow cytometric analysis. The FACS results are representative of three
independent experiments. NC; Negative control.
doi:10.1371/journal.pone.0028011.g002
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proliferation was significantly reduced following TMPP treatment.
However, TMPP-mediated inhibition of the proliferation of U937
cells was reduced by knock-down of IER5 via transfection of IER5
shRNA-#1o r- #2. Moreover, TMPP-mediated IER5 induction
was decreased in U937 cells transfected with IER5 shRNA-#1o r-
#2 (bottom panels) compared to non-transfected cells. Knock-
down of IER5 in other AML cell lines (KG-1, Kasumi-1 and
YRK2), similarly increased cell proliferation (data not shown).
These results show that TMPP inhibits AML cell proliferation
through IER5 induction.
IER5 induced cell cycle arrest in AML cells through direct
binding toCdc25B promoter and decrease ofNF-YB binding
We next determined if the inhibitory effect of IER5 induction
on cell proliferation was mediated by modulation of the expression
of cell cycle regulators such as Cdc25B, CHK1, WEE1, Cyclin B1,
Survivin, KIS, or Aurora B kinase, during the G2/M transition.
As shown in Fig. 4A, induction of the IER5 protein in IER5
cDNA-transfected or in TMPP-treated U937 cells was accompa-
nied by a significant decrease in the level of Cdc25B protein
compared to untransfected cells. IER5 over-expression did not
affect CHK1, WEE1, Cyclin B1, Survivin or Aurora B kinase
expression. In contrast, TMPP treatment reduced the expression
of Cyclin B1, Survivin, and Aurora B kinase. TMPP treatment did
not affect CHK1 and WEE1 expression. Induction of IER5
similarly reduced Cdc25B expression in other AML cell lines (KG-
1, Kasumi-1 and YRK2) (data not shown). These results indicate
that, during TMPP-mediated G2/M cell cycle arrest, TMPP
reduced Cdc25B expression through IER5 induction and that
IER5 is essential for the repression of Cdc25B protein expression
in AML cells. Moreover, IER5 only regulated Cdc25B, and did
not affect other cell cycle regulators of the G2/M transition.
To confirm binding of IER5 to the Cdc25B promoter and more
accurately define its binding site, we performed ChIP analysis in
AML cells using two pairs of oligonucleotides within upstream
from the transcription start site for Cdc25B (Fig. 4B). ChIP analysis
showed that IER5 is highly enriched within a region of the
promoter of Cdc25B, indicating that the Cdc25B gene is a target for
IER5 (Fig. 4C). Moreover, to determine whether the over-
expression of IER5 corresponded to the binding sites of Sp1, Sp3,
and NF-YB within the Cdc25B promoter, ChIP analysis was
performed using antibodies corresponding to Sp1, Sp3, and NF-
YB, which has been reported to be related to p53-mediated
negative regulation of Cdc25B [14]. As shown in Fig. 4D, the
reduced binding of NF-YB on the Cdc25b promoter was observed
in IER5 over-expressed U937 cells compared to untreated and
control DNA transfected cells. On the other hand, the levels of
binding Sp1 and Sp3 on the Cdc25B promoter was not affected in
untreated, control DNA-, or IER5-transfected cells. In addition,
we investigated whether the reduction of NF-YB binding to
Cdc25B promoter interferes with the recruitment of coactivator
p300, which is anti-histone acetyltransferase as a coactivator
known interact with NF-Y [15]. When U937 cell was untreated or
transfected with control DNA, p300 was bound on the Cdc25B
promoter. When IER5 over-expressed in U937 cells, a significant
release of p300 was observed (Fig. 4E). On the other hand, the
DNA methyltransferase DNMT1, which acts as a loading platform
for repressor complexes such as the p53-Sp1 complexes [16] was
not recruited on the Cdc25B promoter in IER5 over-expressed
U937 cells. These ChIP experiments show that the binding of
IER5 on the Cdc25B promoter induced the release of the
coactivator p300, but not the recruitment of the coactivator
DNMT1 via Sp1 interaction, causing the down-regulation of
Cdc25B expression.
Induction of IER5 inhibited colony formation of AML
derived-ALDH
hi/CD34
+ cells
We next examined IER5 mRNA expression in clinical spe-
cimens from AML patients. Hematopoietic progenitor cells from
bone marrow were obtained using flow cytometry based on
ALDH activity, using the substrate Aldefluor as previously
reported. The CD34
+ progenitor cells in the ALDH
hi population
(ALDH
hi/CD34
+ cells) were then sorted using FACS. We isolated
ALDH
hi/CD34
+ cells from bone marrow cells derived from 2
healthy volunteers (#1 and #2) and 2 AML patients (M1 and M2)
(Fig. 5A and B). The percentage of bone marrow cells derived
from healthy volunteers #1 and #2 that were ALDH
low was
98.6% and 97.1%, and that of ALDH
hi cells was 0.37% and
0.52%, respectively. The percentage of the ALDH
hi cells that was
CD34
+ was 84.2% and 81.9%, and that was CD34
- was 14.7%
and 17.5%, respectively. On the other hand, in bone marrow cells
derived from AML patients M1 and M2, the percentage of
ALDH
low cells was 85.4% and 81.1%, respectively, and that of
ALDH
hi cells was 7.4% and 6.7%, respectively. The percentage of
the ALDH
hi cells that was CD34
+ was 87.1% and 80.6%, and that
was CD34
- was 11.4% and 19.3%, respectively.
To confirm that IER5 also modulated the proliferation of AML
progenitor cells from patients, we analyzed the effect of IER5
expression on colony formation of ALDH
hi/CD34
+ cells from
normal healthy volunteer #1 and from an AML patient (M1) prior
to treatment (Fig. 5C). Transfection with IER5 cDNA or treatment
with TMPP induced dramatic decreases in the number of colonies
formed by AML-derived ALDH
hi/CD34
+ cells compared to the
number in untreated cells (Fig. 5C; left panels). In untransfected
AML (M1) cells, the mean number of colonies was 112 (range,
103–119). Following transfection with IER5 cDNA and treatment
with TMPP the mean number of colonies was 27 (range, 21–35)
and 16 (range, 12–27), respectively. In contrast, transfection with
IER5 cDNA only moderately decreased the number of colonies
formed by normal ALDH
hi/CD34
+ cells, compared to untrans-
fected normal ALDH
hi/CD34
+ cells. Thus, the mean number of
colonies in untransfected cells was 46 (range, 39–52) but that in
cells transfected with IER5 cDNA was 22 (range, 18–29). These
results demonstrate that induction of IER5 expression predomi-
nantly inhibited the proliferation of AML-derived ALDH
hi/
CD34
+ cells. In addition, to confirm that IER5-mediated-
inhibition of colony formation of AML-derived ALDH
hi/CD34
+
cells from patients was mediated by an effect on transcription of
the IER5 target gene, we assayed the mRNA expression of the
IER5 target gene Cdc25B in AML-derived ALDH
hi/CD34
+ cells.
As shown in Fig. 5C (right panels), induction of IER5 expression
significantly decreased the expression of Cdc25B mRNA in AML-
derived ALDH
hi/CD34
+ cells, and also decreased the expression
of Cdc25B mRNA in normal ALDH
hi/CD34
+ cells. Moreover, in
AML (M1) ALDH
hi/CD34
+ cells, IER5 over-expression or TMPP
treatment indicated an increase in the percentage of cells in S and
G2/M compared to control cells (Fig 5D). No increase in the sub-
G1 population of these cells was observed. Interestingly, we also
detected an increase (3.1 to 4.2%) in the percentage of polyploid
cells (.4N) in TMPP treated cells compared to control cells. In
addition, as shown in Fig. 5E, DiOC6 fluorescence of AML (M1)
ALDH
hi/CD34
+ cells was not reduced 3 days after transfection
with IER5 cDNA or TMPP treatment, and DiOC6 fluorescence of
IER5 cDNA-transfected or TMPP treated cells compared to
control cells was observed in the almost same levels. Similar results
were obtained using other AML ALDH
hi/CD34
+ cells. (data not
IER5 Induced G2/M Cell Arrest
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expression strongly inhibited colony formation and G2/M cell
cycle arrest in AML-derived ALDH
hi/CD34
+ cells compared to
normal ALDH
hi/CD34
+ cells through induction of Cdc25B
expression.
Colony forming activity of ALDH
hi/CD34
+ cell populations
from AML patients following the induction or depletion of IER5
expression
We examined the effect of induction or knock-down of IER5 on
the colony formzing activity of ALDH
hi/CD34
+ hematopoietic
progenitor cells from an AML patient (M1) (Fig. 6A and C). When
cells were left untreated, the mean number of colonies was 117
(range, 102–126). When the cells were transfected with IER5
cDNA and/or treated with TMPP, the mean numbers of colonies
were 7 (range, 3–11), 28 (range, 20–37), and 22 (range, 14–26),
respectively. Thus colony numbers were dramatically reduced
when ALDH
hi/CD34
+ cells were cultured with TMPP and/or
were transfected with IER5 cDNA. In ALDH
hi/CD34
+ cells
transfected with IER5 shRNA-#1o r- #2, TMPP moderately
reduced colony numbers compared to untransfected cells. More-
over, in each colony derived from ALDH
hi/CD34
+ cells that was
treated with TMPP or transfected with IER5 cDNA, the
expression of IER5 mRNA was increased and the expression of
Cdc25B mRNA was significantly decreased compared to untreated
cells (Fig. 6B). These results demonstrate that during the
proliferation of progenitor cells derived from AML patients,
IER5 induced a reduction in Cdc25B expression.
To further assess the effects of IER5-mediated Cdc25B redu-
ction on colony formation of ALDH
hi/CD34
+ cells from an AML
patient (M1), we investigated whether transfection of Cdc25B DNA
could rescue the colony forming activity of the AML-derived
ALDH
hi/CD34
+ cells transfected with IER5 DNA or treated with
TMPP. ALDH
hi/CD34
+ cells were transfected with IER5 cDNA
or were treated with TMPP. As shown in Fig. 6D and F, either
TMPP treatment or IER5 over-expression inhibited colony
formation of AML-derived ALDH
hi/CD34
+ cells. In contrast,
over-expression of Cdc25B in ALDH
hi/CD34
+ cells increased the
number of colonies compared to untransfected cells. Moreover,
the expression level of IER5 mRNA was not affected in any colony
derived from ALDH
hi/CD34
+ cells that was transfected with
Cdc25B DNA (Fig. 6E). Similar results were obtained using AML
(M2) ALDH
hi/CD34
+ cells. These findings suggest that the
transcriptional repression mediated by IER5 regulated Cdc25B
expression levels, and, subsequently, decreased the expression of
Cdc25B, resulting in inhibition of colony formation.
The reduction of NF-YB binding to the Cdc25B promoter
by IER5 causes the decrease of Cdc25B expression
Finally, to confirm binding of IER5 to the Cdc25B promoter in
AML-derived ALDH
hi/CD34
+ cells, we also performed ChIP
analysis in ALDH
hi/CD34
+ cells purified from one AML patient
(AML: M1) (Fig. 7). ChIP analysis showed that IER5 is also highly
enriched within a region of the promoter of Cdc25B (Fig. 7, left
panel). Moreover, to determine whether the over-expression of
IER5 corresponded to the binding site of NF-YB within the
Cdc25B promoter, ChIP analysis was performed using the anti-NF-
YB antibody. The result shows that the reduced binding of NF-YB
on the Cdc25b promoter was observed in IER5 over-expressed
AML-derived ALDH
hi/CD34
+ cells compared to untreated and
control DNA transfected cells (Fig. 7, middle panel). In addition, a
significant release of p300 was also observed in IER5 over-
expressed AML-derived ALDH
hi/CD34
+ cells, (Fig. 7, right
panel). These results show that the binding of IER5 on the
Cdc25B promoter induced the release of the coactivator p300,
causing the down-regulation of Cdc25B expression in AML-
derived ALDH
hi/CD34
+ cells.
Discussion
We investigated the role of IER5 in inhibition of the growth of
AML cells induced by treatment with TMPP. We demonstrated,
for the first time, that TMPP induces the expression of IER5 and
inhibits AML cell proliferation via IER5-mediated transcriptional
repression of Cdc25B. Combined with the results of our previous
study that TMPP-mediated FOXM1 repression induced G2/M
cell cycle arrest, our results provide in vitro evidence to support a
role for FOXM1 as an oncogene in AML cells, and to support the
fact that its down-regulation inhibits the proliferation of esta-
blished AML cell lines and primary AML cells.
IER5, which encodes a 308-amino acid member of the
immediate-early class of signal transduction proteins, is induced
by growth factors and mediates the cellular response to mitogenic
signals [6]. IER5 also functions as a transcriptional regulator by
binding to DNA or by mediating nuclear protein-protein inter-
actions [6]. Moreover, it has been reported that ionizing radiation
induces IER5 mRNA expression in a dose- and time-dependent
manner, and that suppression of IER5 increases the proliferation
of HeLa cells and mitigates the inhibition of proliferation induced
by exposure to radiation, thereby increasing the resistance of
HeLa cells to radiation. In contrast, increased expression of IER5
reportedly disturbed the cell cycle checkpoint and sensitized cells
to radiation [11]. These previous results have shown that IER5
expression plays a role in the induction of cell death that is caused
by radiation. However, the biochemical pathway and mechanisms
of IER5 function in regulation of the cell cycle remain unclear. In
this study, we investigated the involvement of IER5 in the cell
cycle and in proliferation of AML cells and AML-derived leukemic
progenitor cells. We found that treatment with TMPP induced the
expression of IER5 mRNA and that over-expression of IER5 in
AML cells inhibited their proliferation. Moreover, suppression of
IER5 expression in AML cells using shRNA increased the pro-
liferation of AML cells, and mitigated TMPP-mediated inhibition
of proliferation compared to untransfected AML cells. We also
found that the both IER5 over-expression and induction of IER5
expression by TMPP treatment induced an increase in the
population of AML cells and primary AML blastic cells in the
Figure 4. IER5 induced G2/M cell cycle arrest through direct binding to Cdc25B promoter in AML cells. A. U937 cells were transfected
with control DNA, IER5 cDNA, or were treated with TMPP (5 mMo r1 0mM). The cells were harvested after 3 days, and the expression of the indicated
cell cycle regulating proteins was analyzed by SDS-PAGE followed by Western blotting using the indicated specific antibodies. Blotting of Actin was
used as a loading control. B. Schematic representation of the human Cdc25B promoter regions, indicating sites for Sp1, Sp3, and NF-YB motifs,
amplified from the precipitated DNA by specific primer sets 1 and 2. C. ChIP analysis for IER5 in the Cdc25B promoter. D & E. IER5-dependent changes
in Sp1, Sp3 and NF-YB binding (E), and the bindings of coactivators, DNMT1 and p300, to interact with Sp1 and NF-YB, respectively (F) in Cdc25B
promoter. U937 cells were either untransfected or were transfected with the control DNA or IER5 DNA. After 3 days culture, cells were cross-linked
with 1% formaldehyde and ChIP was performed with either control antibody (IgG) or the anti-IER5 antibody. The precipitated DNA was then assayed
by PCR using pairs (primer set 1 and 2) of oligonucleotides encompassing specific regions of the Cdc25B promoter. The values of ChIP efficiencies are
given as % of input.
doi:10.1371/journal.pone.0028011.g004
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cells, 3 days after transfection. These data are consistent with the
established notion that IER5 is a key regulator of cell cycle
checkpoints [11].
Because induction or over-expression of IER5 expression
induced G2/M cell cycle arrest and inhibited AML cell
proliferation, we considered that identification of genes regulated
by IER5 would facilitate an understanding of the roles IER5 plays
in AML cell proliferation. We previously showed that knock-down
of FOXM1, or TMPP treatment, markedly decreased the protein
expression of the mitotic regulators Skp2, Cdc25B, Cyclin B1,
Survivin, KIS, Aurora-B kinase in AML cells [1,2]. Diminished
expression of these mitotic regulators results in a block in mitotic
progression or proliferation, and leads to an accumulation of
p27
Kip1 and p21
Cip1 proteins [1,2]. Moreover, the expression of
Cdc25B is known to be increased in AML cells [13]. In this study,
we found that IER5 over-expression markedly decreased Cdc25B
protein expression, but not the expression of CHK1, WEE1,
Cyclin B1, Survivin, and Aurora kinase B proteins. Thus, of the
genes in the G2/M specific gene cluster, among which are
essential regulators of mitosis, IER5 predominantly controls the
expression of Cdc25B. Therefore, IER5 induction would be
expected to strongly induce G2/M cell cycle arrest in AML cells.
In addition, we observed the number of cells in both S- and G2/
M-phase. In cell cycle, the G2/M checkpoint is a barrier to
aberrant cellular proliferation, and arrests damaged cells to allow
time for repair [17]. The expression of Cdc25B is initiated during
S-phase, peaking in G2 and declining in mitosis [18]. Cdc25B has
been reported to play a role in the control of entry into mitosis
after a DNA damage-activated checkpoint in cells [14,19,20]. In
AML cells, the Cdc25B participates in the G2/M checkpoint
recovery and its expression is upregulated, and the reduction of
Cdc25B expression induced the cell number of both S- and G2/
M-phase in AML cells [14]. Our data are consistent with the data
of the report [14]. Therefore, when TMPP induced the IER5
expression, the Cdc25B expression is reduced and G2/M
checkpoint is induced, and then the cells with S- and G2/M-
phase DNA contents is increased. Moreover, the population of
G2/M distribution is more significantly increased than that of S-
phase.
Cdc25 phosphatases, which are dual specificity phosphatases
and important regulators of G2/M transition regulators, regulate
entry into mitosis by regulating the activation of CDK1/cyclin B
[21]. The Cdc25 phosphatases activate the mitotic CDK
complexes by dephosphorylating the inhibitory Thr14 and
Tyr15 residues on CDK1 and CDK2 [22]. There are three
isoforms of the Cdc25 phosphatase; Cdc25A, Cdc25B and
Cdc25C, and all three isoforms have roles in G2/M progression.
It was previously believed that Cdc25A acts at the G1/S
transition, whereas Cdc25B and Cdc25C function mainly at the
G2/ M transition [21,23]. However, recent studies suggest that all
three CDC25 phosphatases function as regulators of both G1/S
and G2/M transitions [23]. It has also been reported that only
depletion of Cdc25A and Cdc25B delays entry into mitosis [24].
In contrast, all three Cdc25 isoforms are targets for checkpoint
kinase inactivation [25]. Cdc25A is destabilized by CHK1
phosphorylation in response to DNA damage [26]. Cdc25B is
specifically required for exit from the G2 phase checkpoint arrest
[27], and its stability has also been linked to responses to damage
[28]. Thus, it is believed that aberrant regulation of Cdc25
phosphatases causes tumorigenesis via dysregulation of the cell
cycle [22,29–31]. It has been suggested that Cdc25 phosphatases
are involved in deficient checkpoints during mitosis in malignant
transformation [22,32]. The activity of the Cdc25 phosphatases is
regulated by their phosphorylation status, their expression level
and their subcellular localization [22,32]. Abnormal expression of
Cdc25B has been reported in a number of carcinomas, such as
non-small cell lung cancer [29], colorectal carcinomas [32],
ovarian [33], esophageal [34,35], prostate [36], gastric [37] and
pancreatic [38] cancers. Thus, overexpression of Cdc25B is
believed to contribute to tumorigenesis by enhancing tumor
malignancy [21]. However, it remains unknown how Cdc25B
expression is translationally regulated. Currently, it has been
reported that Cdc25B is negatively regulated by p53 through Sp1
and NF-Y transcription factors [14]. The analysis of Cdc25B
promoter shows that the down-regulation of Cdc25B by p53 is
needed for the Sp1/Sp3 and NF-Y binding sites in Cdc25B
promoter, p53 binds to the Cdc25B promoter and mediates
transcriptional attenuation via the Sp1 and NF-Y transcription
factors. We have examined the relationship between IER5 and
Cdc25B promoter, and binding of Sp1 and NF-YB, which is one of
NF-Y subunits, by using ChIP assay in AML cell lines and AML-
derived ALDH
hi/CD34
+ cells. In leukemia cells, IER5 directly
binds to Cdc25B promoter. Moreover, when IER5 over-expressed,
the significantly reduced binding of NF-YB on the Cdc25B
promoter the release of anti-histone acetyltransferase p300, which
is known as a coactivator of NF-Y [15], was observed at upstream
of 1st exon of Cdc25B. On the other hand, we did not observe that
Figure 5. IER5 inhibits the colony formation of ALDH
hi/CD34
+ cells isolated from AML patients. A. Selection of ALDH
hi/CD34
+
hematopoietic progenitor cells from the bone marrow of two healthy volunteers (#1 and #2) by FACS sorting. Region P denotes populations of
ALDH
hi cells. Region R and S denote populations of CD34
+ and CD34
- cells in the ALDH
hi population (Region P), respectively. Negative control, light
grey region; CD34-PE staining, dark grey region. B. Selection of ALDH
hi/CD34
+ hematopoietic progenitor cells from the bone marrow of two AML
patients (M1 and M2) by FACS sorting. Region P denotes populations of ALDH
hi cells. Region R and S denote populations CD34
+ and CD34
- cells in
the ALDH
hi population (Region P), respectively. Negative control, light grey region; CD34-PE staining, dark grey region. C. ALDH
hi/CD34
+ cells were
purified from a healthy volunteer (#1) and an AML patient (M1), and were cultured in semisolid methylcellulose media. The ALDH
hi/CD34
+ cells from
each source were left untransfected or were transfected with IER5 cDNA, or treated with TMPP (5 mM). After 14 days culture, the colony forming
ability of the cells was analyzed (left upper panel) and the cells were viewed using phase-contrast microscopy. Original magnification64 (left bottom
panels). Their mRNA expression of IER5 and Cdc25B was assessed using RT-PCR and quantitative RT-PCR (right panels). Colonies formed by these
ALDH
hi/CD34
+ cells (3610
2 to 5610
2 cells/plate) were counted following plating in semisolid methylcellulose media. Colony formation was evaluated
by determination of colony counts as a percentage of the corresponding control. The results are the means 6 SD of three independent experiments.
*P,0.01 compared with untreated control cells. RT-PCR results representative of three independent experiments are shown. GAPDH mRNA
expression is shown as an internal control. The ALDH
hi/CD34
+ cells whose IER5 mRNA expression was analyzed by quantitative RT-PCR were derived
from an AML patient (M1). The levels of the quantified RT-PCR products were normalized to GAPDH expression in the same sample and were then
expressed relative to the mRNA level of a normal control which was assigned a value of 1. D and E. Cell cycle analysis (D) and changes of
mitochondrial membrane potential (DYm) (E) in IER5 overexpressed or TMPP treated AML-derived ALDH
hi/CD34
+ cells. ALDH
hi/CD34
+ cells were
purified from an AML patient (M1), and were then transfected with IER5 cDNA or were treated with TMPP (5 mM). The IER5-transfected or TMPP-
treated cells were harvested after 3 days. The cell cycle distribution and the DYm of the ALDH
hi/CD34
+ cells was analyzed using flow cytometric
analysis. The FACS results are representative of three independent experiments. NC; Negative control.
doi:10.1371/journal.pone.0028011.g005
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that the binding of IER5 on the Cdc25B promoter induced the
recruitment of coactivator p300, causing the inhibition of AML
cell proliferation and colony formation of AML-derived ALDH
hi/
CD34
+ cells through the down-regulation of Cdc25B.
We performed a colony formation assay using the ALDH
hi/
CD34
+ progenitor cells derived from two normal healthy
volunteers and two AML patients (M1 and M2). The number of
colonies was moderately reduced when normal ALDH
hi/CD34
+
progenitor cells were transfected with IER5 cDNA. In contrast,
colony numbers were significantly reduced when ALDH
hi/CD34
+
AML progenitor cells were transfected with IER5 cDNA or were
treated with TMPP. Moreover, the relative expression of Cdc25B
was decreased in colony forming cells when ALDH
hi/CD34
+
AML progenitor cells were treated with TMPP or were transfected
with IER5 cDNA. Moreover, when ALDH
hi /CD34
+ AML
progenitor cells were transfected with IER5 shRNA, the inhibitory
effects of TMPP on colony formation by TMPP were decreased in
colony forming cells. These results indicate that increased
expression of IER5 induced by TMPP reduced the number of
colony forming cells derived from AML progenitor cells through a
reduction in Cdc25B expression. Consistent with the idea that
IER5 and TMPP effects were mediated by a decrease in Cdc25B,
we found that over-expression of Cdc25B rescued both the
inhibitory effects of TMPP treatment and those of IER5 over-
expression in ALDH
hi/CD34
+ AML progenitor cells, resulting in
recovery of the colony forming activity of AML-derived ALDH
hi/
CD34
+ cells.
In conclusion, this study shows for the first time that IER5 over-
expression strongly inhibited AML-derived ALDH
hi/CD34
+ cell
proliferation and colony formation through a reduction in Cdc25B
expression, resulting in induction of G2/M cell cycle arrest.
Moreover, our data show that the reduction of NF-YB by IER5
inhibited the AML cell proliferation through the release of p300.
Therefore, IER5 induction could be an attractive potential target
for AML therapy.
Materials and Methods
Chemical synthesis and reagents
TMPP was prepared as previously described by reacting 4-
bromo-3-methyl-1-phenyl-2-phospholene 1-oxide with bromine
[1]. The reaction mixtures were extracted with chloroform,
washed with saturated NaCl solution, and dried with anhydrous
sodium sulfate. These reaction agents were then dissolved in
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO) and
diluted in culture medium immediately before use. The final
concentration of DMSO in all experiments was less than 0.01%,
and all treatment conditions were compared with vehicle controls.
Cytarabine (cytosine arabinoside, Ara-c) was purchased from
Sigma-Aldrich.
Cells and cell cultures
The human leukemia cell lines, KG-1, Kasumi-1 and U937,
were purchased from the American Type Culture Collection
(ATCC, Manassas, VA). YRK2 cells were harvested in our
Figure 6. IER5 expression inhibited the colony formation of AML ALDH
hi/CD34
+ cells through the regulation of Cdc25B expression.
A. ALDH
hi/CD34
+ cells were purified from an AML patient (M1) and were cultured in semisolid methylcellulose media. The ALDH
hi/CD34
+ cells were
either untransfected or were transfected with IER5 cDNA or with shRNA-#1, or -#2. After 14 days culture with or without TMPP (5 mM), the cells were
then analyzed for their colony forming ability. Colony formation of these ALDH
hi/CD34
+ cells (3610
2 to 5610
2 cells/plate) was assessed after plating
in semisolid methylcellulose media. B. Analysis of the mRNA expression of IER5 and Cdc25B in each colony using QRT-PCR and RT-PCR. C. The cells
were viewed using phase-contrast microscopy after 14 days culture with or without TMPP (5 mM). Original magnification 64. D. ALDH
hi/CD34
+ cells
were purified from an AML patient (M1) and were cultured in semisolid methylcellulose media. The ALDH
hi/CD34
+ cells were either untransfected or
were transfected with IER5 cDNA or Cdc25B cDNA. After 14 days culture with or without TMPP (5 mM), the cells were then analyzed for their colony
forming ability. Colony formation of these ALDH
hi/CD34
+ cells (3610
2 to 5610
2 cells/plate) was assessed after plating in semisolid methylcellulose
media. Colony formation was evaluated as a percentage of the corresponding control. E. Analysis of the mRNA expression of IER5 and Cdc25B in each
colony using QRT-PCR and RT-PCR. The levels of the QRT-PCR products were normalized to GAPDH expression in the same sample and were then
expressed relative to the mRNA level of a normal control which was assigned a value of 1. RT-PCR results representative of three independent
experiments are shown. GAPDH mRNA expression is shown as an internal control. The results are the means 6 SD of three independent experiments.
*P,0.01 compared with untreated control cells. F. The cells transfected with Cdc25B or IER5 cDNA were viewed using phase-contrast microscopy after
14 days culture with or without TMPP (5 mM). Original magnification 64.
doi:10.1371/journal.pone.0028011.g006
Figure 7. IER5-mediated negative regulation of Cdc25B expression through the reduction of NF-YB binding. The ALDH
hi/CD34
+ cells
purified from two AML patients (AML: M1) were either untransfected or were transfected with control DNA or IER5 DNA. After 14 days culture, cells
were cross-linked with 1% formaldehyde and ChIP was performed with either control antibody (IgG) or the anti-IER5 antibody. The precipitated DNA
was then assayed by real-time PCR using pairs (primer set 2) of oligonucleotides encompassing specific region of the Cdc25B promoter (left panel).
IER5-dependent changes in NF-YB binding (middle panel), and the bindings of coactivators, p300 (right panel) in Cdc25B promoter. The values of ChIP
efficiencies are given as % of input.
doi:10.1371/journal.pone.0028011.g007
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can-British (FAB) classification; M5a) patients after obtaining
informed consent. The KG-1, U937, and YRK2 cells were
cultured in RPMI 1640 media containing 10% heat-inactivated
fetal bovine serum (FBS), 2 mM L-glutamine, 100 mg/ml
streptomycin, and 200 U/ml penicillin (GIBCO-BRL, Gaithers-
burg, MD). Kasumi-1 cells were grown in RPMI1640 containing
20% FBS, 2 mM L-glutamine, 100 mg/ml streptomycin, and
200 U/ml penicillin. Primary leukemia cell specimens were
obtained from the bone marrow of two AML patients (FAB
classification; M1 and M2) before the start of any treatment, and
normal hematopoietic cells were extracted from healthy donors
(n=2) after obtaining informed consent, which was written. We
obtained ethics approval for this study from the Institutional
Review Board of Hamamatsu University School of Medicine.
Mononuclear cells (MNCs) were purified by Ficoll-Hypaque
density-gradient centrifugation.
Purification of leukemic blast cells based on ALDH
activity and CD34 expression
For 2-color staining, MNCs were stained with anti-CD34-
phycoerythrin (PE)-conjugated antibody (Becton Dickinson, San
Jose, CA) and the Aldefluor reagent (StemCo Biomedical,
Durham, NC) according to the manufacturer’s specifications and
were separated using fluorescence-activated cell sorting (FACS).
The ALDH
hi cells were gated, and the CD34
+ cells in the gated
ALDH
hi population were sorted on a fluorescence-activated cell
sorter (Becton Dickinson). Sorted ALDH
hi/CD34
+ cell popula-
tions were collected in methylcellulose media (Methocut H4435;
StemCell Technologies, Inc., Vancouver, BC, Canada).
RT-PCR and Quantitative Real-Time PCR (QRT-PCR)
Total RNA was extracted from cells using the RNeasy system
(Qiagen, Tokyo, Japan), and 2 mg RNA was reverse transcribed
using a first strand cDNA synthesis kit (Roche, Indianapolis, IN).
PCR was performed using a DNA thermal cycler (model PTC
200; MJ Research, Watertown, MA). The sense and anti-sense
oligonucleotide sequences respectively of each primer were as
follows: IER5,5 9-GGACGACACCGACGAGGAG-39, and 59-
GCTTTTCCGTAGGAGTCCCG-39; Cdc25B,5 9-TCCAGG-
GAGAGAAGGTGTCT-39 and 59- TGTCCACAAATCCGT-
CATCT-39; GAPDH,5 9- GAACAGCAACGAGTACCGGGTA-
39 and 59-CCCATGGCCTTGACCAAGGAG-39. PCR condi-
tions for IER5, Cdc25B, and GAPDH were: 28 cycles of dena-
turation at 96uC for 30 sec, annealing at 56uC for 30 sec, and
extension at 72uC for 30 sec. All RT-PCR experiments were
performed in duplicate. QRT-PCR was performed using SYBER-
Green dye and an ABI PRISM 7700 Sequence detector (Perkin-
Elmer/Applied Biosystems, Foster City, CA).
Plasmids and RNA interference
Full-length cDNAs encoding human IER5 and Cdc25B were
obtained by RT-PCR using human bone marrow cDNA (BD
Biosciences Clontech, Palo Alto, CA) as a template and were
cloned into the eukaryotic expression vector pcDNA3.1/V5-His
(Invitrogen, Carlsbad, CA). Sequences of recombinant IER5 and
Cdc25B cDNAs were verified using automated sequencing.
The vectors for RNA interference (RNAi) specific for human
IER5 were constructed based on the piGENE PUR hU6 vector
(iGENE Therapeutics, Tsukuba, Japan), according to the manu-
facturer’s instructions. We used the following targeting sequences:
IER5 shRNA #1; 59-CCTCATCAGCATCTTCGGT-39, and
IER5 shRNA #2; 59-CTGCATAAGAACCTCCTG-39. The
scrambled shRNA sequence, 59-GGACGAACCTGCTGAGA-
TAT-39, was used as a control. Vectors were transfected into cells
by using the Lipofectamine 2000 kit (Life Technologies, Gaithers-
burg, MD), according to the manufacturer’s instructions. The
transfection procedure was repeated 12 h after the first transfec-
tion, and cells were harvested at 48 and 72 h after the initial
transfection. Knockdown efficiency was consistently 60% to 70%,
as determined by RT-PCR measurement of IER5 mRNA.
Cell proliferation and viability assay
KG-1, Kasumi-1, U937 and YRK2 cells were transfected with
IER5 shRNA-#1o r- #2, with scrambled shRNA, or were left
untreated. After 3 days incubation, the cells were plated in six-well
plates at a density of 1610
4 cells per well. Cell proliferation was
measured by counting cells using a hemocytometer. AML cells
were seeded in 96-well, flat-bottom microplates at a density of
2610
4 cells per well. The cells were untransfected or were
transfected with scrambled shRNA or with IER5 shRNA-#1o r-
#2. Cells grown in complete medium without transfection were
used as controls. Cell proliferation was also assessed by counting of
viable cells on the indicated days using trypan blue (Sigma-
Aldrich) exclusion. The number of nonviable cells was determined
by counting of live cells that did not uptake trypan blue in a
hemocytometer and are reported as the percentage of untrans-
fected control cells. Each data point was performed in triplicate,
and the results are reported as mean counts 6 SD.
Detection of changes in mitochondrial membrane
potential (DYm)
To detect DYm, cells (1610
4 cells/well) that were transfected
with IER5 cDNA or treated with TMPP were incubated in 24-well
plates. After 3 days, cells were labeled with DiOC6 (40 nM in
culture medium) at 37uC for 20 min. After washing in PBS,
cellular uptake of DiOC6 was analyzed using flow cytometry.
Cell cycle analysis
Cellular DNA content was analyzed using propidium iodide (PI)
(Sigma-Aldrich) staining. The cells were stained with 50 mg/ml PI
on day 3 post-transfection. The relative DNA content per cell was
measured using flow cytometry and an Epics Elite flow cytometer
(Coulter Immunotech, Marseille, France). The percentage of cells
in G1, S, and G2/M phases was calculated using the ModFit
program (Becton Dickinson, San Jose, CA).
Western blot analysis
Cells transfected with scrambled shRNA or with IER5 shRNA-
#1o r- #2 were harvested after 3 days. Western blot analysis was
performed using the following antibodies: goat polyclonal anti-
IER5 (Abcam, Cambridge, UK); Rabbit polyclonal anti-Cdc25B,
anti-CHK1, anti-WEE1 and anti-Aurora-B; mouse monoclonal
anti-Cyclin B1 and anti-Survivin, all from Santa Cruz. To ensure
equal protein loading, Western blotting of actin, used as an
internal control, was carried out using a mouse monoclonal anti-
Actin antibody (C-4; ICN, Aurora, OH).
Chromatin immunoprecipitation assay
U937 and AML-derived ALDH
hi/CD34
+ cells were untrans-
fected or transfected with control DNA, or IER5 DNA. After 3
days, the cells were crosslinked with 1% formaldehyde for 15
minutes at room temperature, washed twice with ice-cold
phosphate-buffered saline (PBS), and harvested. ChIP assay was
performed by using Simple ChIP Enzymatic Chromatin IP Kit
(Cell Signaling Technology, Beverly, MA), according to the
IER5 Induced G2/M Cell Arrest
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input DNA were treated with RNase A (Sigma-Aldrich) and
proteinase K (Roche), and extracted with phenol:chloroform. For
ChIP analysis of IER5, Sp1, Sp3, NF-YB, DNMT1, and p300,
anti-IER5 antibody (Abcam), anti-Sp1 (Santa Cruz), anti-Sp3
(Santa Cruz), anti-NF-YB (Santa Cruz), anti-DNMT1 (Abcam),
and anti-p300 (Santa Cruz) with protein G-conjugated agarose
beads were incubated to make each antibody-conjugated agarose
beads. Anti-rabbit IgG antibody was used as an isotype control.
DNA that underwent ChIP was analyzed by conventional and
quantitative PCR, and data are presented as percentage of input as
determined with Applied Biosystem’s SDS software Absolute
Quantification protocol. Sense and anti-sense oligonucleotide
sequences respectively of each primer for PCR were as follows:
Set 1 (nucleotide position; -424 to -126), (S1) 59-AGCCGGGTT-
GACAGAGGGAGAC-39, and (AS1) 59-AACGGTGGAAC-
TAGGAATGGA–39, Set 2 (nucleotide position; -96 to +120),
(S2) 59- AAGAGCCCATCAGTTCCGCTTG -39, and (AS2) 59-
CCCATTTTACAGACCTGGACGC -39.
Colony forming assays
Colony forming assays were performed by plating purified
populations of cells at concentrations ranging from 1610
3 to
2610
3 cells into methylcellulose media (Methocut H4435; Stem
Cell Technologies). Colonies were enumerated under light
microscopy (Zeiss, Munchen, Germany) following incubation for
14 days at 37 uC and 5% CO2.
Isolation of progenitor cells and QRT-PCR of progenitor
cells
Following colony formation, each colony was harvested using a
glass syringe, and all cells of the same colony were pooled and
washed. An RNeasy system was used to extract total RNA from
approximately 5610
4 cells from each colony.
Statistical analysis
Data are representative of at least three experiments with
essentially similar results. These results are expressed as the means
6 standard deviations (SD) or standard error of the means as
indicated. Statistical analyses of the data were performed using
Student’s t-test. P values less than 0.05 were considered statistically
significant.
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